Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
Next >
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
July 26, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
July 24, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
July 20, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
July 12, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in PSYCH Symposium London 2023
June 30, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
June 29, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
June 27, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
June 27, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the 2023 MAPS Psychedelic Science Conference
June 21, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Provides Corporate Update
June 08, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
June 05, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
May 30, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
May 24, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
May 09, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate at the 26th Annual Milken Institute Global Conference
April 28, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
April 12, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
March 02, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
February 28, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Streamlined Clinical Alignment
February 22, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
February 14, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
February 01, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Host Virtual R&D Day on February 28, 2023
January 26, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
January 18, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
January 12, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
January 08, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Highlights 2022 Accomplishments and Milestones
December 20, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
December 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
November 15, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.